Update of newborn screening and therapy for congenital hypothyroidism

Susan R. Rose, Rosalind S. Brown, Thomas Foley, Paul B. Kaplowitz, Celia I. Kaye, Sumana Sundararajan, Surendra K. Varma, Stuart J. Brink, William L. Clarke, Janet Silverstein, Rosemary Scales, Laura Laskosz, G. Bradley Schaefer, Marilyn J. Bull, Gregory M. Enns, Jeffrey R. Gruen, Joseph H. Hersh, Nancy J. Mendelsohn, Howard M. Saal, James D. GoldbergJames W. Hanson, Michele A. Lloyd-Puryear, Sonja A. Rasmussen, Paul Spire, Joseph G. Hollowell, Victor J. Bernet, Ruth M. Belin, Kenneth D. Burman, Henry G. Fein, James V. Hennessey, Steven H. Lamm, Marvin L. Mitchell, Hee Myung Park, Richard J. Robbins, Rebecca S. Bahn, David V. Becker, Jayne A. Franklyn, Jacob Robbins, Lester Van Middlesworth, Lynne L. Levitsky, Alan D. Rogol, Sally Radovich

Research output: Contribution to journalArticle

442 Citations (Scopus)

Abstract

Unrecognized congenital hypothyroidism leads to mental retardation. Newborn screening and thyroid therapy started within 2 weeks of age can normalize cognitive development. The primary thyroid-stimulating hormone screening has become standard in many parts of the world. However, newborn thyroid screening is not yet universal in some countries. Initial dosage of 10 to 15 μg/kg levothyroxine is recommended. The goals of thyroid hormone therapy should be to maintain frequent evaluations of total thyroxine or free thyroxine in the upper half of the reference range during the first 3 years of life and to normalize the serum thyroid-stimulating hormone concentration to ensure optimal thyroid hormone dosage and compliance. Improvements in screening and therapy have led to improved developmental outcomes in adults with congenital hypothyroidism who are now in their 20s and 30s. Thyroid hormone regimens used today are more aggressive in targeting early correction of thyroid-stimulating hormone than were those used 20 or even 10 years ago. Thus, newborn infants with congenital hypothyroidism today may have an even better intellectual and neurologic prognosis. Efforts are ongoing to establish the optimal therapy that leads to maximum potential for normal development for infants with congenital hypothyroidism. Remaining controversy centers on infants whose abnormality in neonatal thyroid function is transient or mild and on optimal care of very low birth weight or preterm infants. Of note, thyroid-stimulating hormone is not elevated in central hypothyroidism. An algorithm is proposed for diagnosis and management. Physicians must not relinquish their clinical judgment and experience in the face of normal newborn thyroid test results. Hypothyroidism can be acquired after the newborn screening. When clinical symptoms and signs suggest hypothyroidism, regardless of newborn screening results, serum free thyroxine and thyroidstimulating hormone determinations should be performed.

Original languageEnglish (US)
Pages (from-to)2290-2303
Number of pages14
JournalPediatrics
Volume117
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Congenital Hypothyroidism
Newborn Infant
Thyrotropin
Thyroxine
Thyroid Gland
Hypothyroidism
Thyroid Hormones
Therapeutics
Very Low Birth Weight Infant
Child Development
Serum
Premature Infants
Intellectual Disability
Nervous System
Compliance
Signs and Symptoms
Reference Values
Hormones
Physicians

Keywords

  • Congenital hypothyroidism
  • Newborn screening
  • Thyroid hormone
  • Thyroid-stimulating hormone

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Rose, S. R., Brown, R. S., Foley, T., Kaplowitz, P. B., Kaye, C. I., Sundararajan, S., ... Radovich, S. (2006). Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics, 117(6), 2290-2303. https://doi.org/10.1542/peds.2006-0915

Update of newborn screening and therapy for congenital hypothyroidism. / Rose, Susan R.; Brown, Rosalind S.; Foley, Thomas; Kaplowitz, Paul B.; Kaye, Celia I.; Sundararajan, Sumana; Varma, Surendra K.; Brink, Stuart J.; Clarke, William L.; Silverstein, Janet; Scales, Rosemary; Laskosz, Laura; Schaefer, G. Bradley; Bull, Marilyn J.; Enns, Gregory M.; Gruen, Jeffrey R.; Hersh, Joseph H.; Mendelsohn, Nancy J.; Saal, Howard M.; Goldberg, James D.; Hanson, James W.; Lloyd-Puryear, Michele A.; Rasmussen, Sonja A.; Spire, Paul; Hollowell, Joseph G.; Bernet, Victor J.; Belin, Ruth M.; Burman, Kenneth D.; Fein, Henry G.; Hennessey, James V.; Lamm, Steven H.; Mitchell, Marvin L.; Park, Hee Myung; Robbins, Richard J.; Bahn, Rebecca S.; Becker, David V.; Franklyn, Jayne A.; Robbins, Jacob; Van Middlesworth, Lester; Levitsky, Lynne L.; Rogol, Alan D.; Radovich, Sally.

In: Pediatrics, Vol. 117, No. 6, 06.2006, p. 2290-2303.

Research output: Contribution to journalArticle

Rose, SR, Brown, RS, Foley, T, Kaplowitz, PB, Kaye, CI, Sundararajan, S, Varma, SK, Brink, SJ, Clarke, WL, Silverstein, J, Scales, R, Laskosz, L, Schaefer, GB, Bull, MJ, Enns, GM, Gruen, JR, Hersh, JH, Mendelsohn, NJ, Saal, HM, Goldberg, JD, Hanson, JW, Lloyd-Puryear, MA, Rasmussen, SA, Spire, P, Hollowell, JG, Bernet, VJ, Belin, RM, Burman, KD, Fein, HG, Hennessey, JV, Lamm, SH, Mitchell, ML, Park, HM, Robbins, RJ, Bahn, RS, Becker, DV, Franklyn, JA, Robbins, J, Van Middlesworth, L, Levitsky, LL, Rogol, AD & Radovich, S 2006, 'Update of newborn screening and therapy for congenital hypothyroidism', Pediatrics, vol. 117, no. 6, pp. 2290-2303. https://doi.org/10.1542/peds.2006-0915
Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006 Jun;117(6):2290-2303. https://doi.org/10.1542/peds.2006-0915
Rose, Susan R. ; Brown, Rosalind S. ; Foley, Thomas ; Kaplowitz, Paul B. ; Kaye, Celia I. ; Sundararajan, Sumana ; Varma, Surendra K. ; Brink, Stuart J. ; Clarke, William L. ; Silverstein, Janet ; Scales, Rosemary ; Laskosz, Laura ; Schaefer, G. Bradley ; Bull, Marilyn J. ; Enns, Gregory M. ; Gruen, Jeffrey R. ; Hersh, Joseph H. ; Mendelsohn, Nancy J. ; Saal, Howard M. ; Goldberg, James D. ; Hanson, James W. ; Lloyd-Puryear, Michele A. ; Rasmussen, Sonja A. ; Spire, Paul ; Hollowell, Joseph G. ; Bernet, Victor J. ; Belin, Ruth M. ; Burman, Kenneth D. ; Fein, Henry G. ; Hennessey, James V. ; Lamm, Steven H. ; Mitchell, Marvin L. ; Park, Hee Myung ; Robbins, Richard J. ; Bahn, Rebecca S. ; Becker, David V. ; Franklyn, Jayne A. ; Robbins, Jacob ; Van Middlesworth, Lester ; Levitsky, Lynne L. ; Rogol, Alan D. ; Radovich, Sally. / Update of newborn screening and therapy for congenital hypothyroidism. In: Pediatrics. 2006 ; Vol. 117, No. 6. pp. 2290-2303.
@article{5d9817b1df7946aeb385343d7f0a6af2,
title = "Update of newborn screening and therapy for congenital hypothyroidism",
abstract = "Unrecognized congenital hypothyroidism leads to mental retardation. Newborn screening and thyroid therapy started within 2 weeks of age can normalize cognitive development. The primary thyroid-stimulating hormone screening has become standard in many parts of the world. However, newborn thyroid screening is not yet universal in some countries. Initial dosage of 10 to 15 μg/kg levothyroxine is recommended. The goals of thyroid hormone therapy should be to maintain frequent evaluations of total thyroxine or free thyroxine in the upper half of the reference range during the first 3 years of life and to normalize the serum thyroid-stimulating hormone concentration to ensure optimal thyroid hormone dosage and compliance. Improvements in screening and therapy have led to improved developmental outcomes in adults with congenital hypothyroidism who are now in their 20s and 30s. Thyroid hormone regimens used today are more aggressive in targeting early correction of thyroid-stimulating hormone than were those used 20 or even 10 years ago. Thus, newborn infants with congenital hypothyroidism today may have an even better intellectual and neurologic prognosis. Efforts are ongoing to establish the optimal therapy that leads to maximum potential for normal development for infants with congenital hypothyroidism. Remaining controversy centers on infants whose abnormality in neonatal thyroid function is transient or mild and on optimal care of very low birth weight or preterm infants. Of note, thyroid-stimulating hormone is not elevated in central hypothyroidism. An algorithm is proposed for diagnosis and management. Physicians must not relinquish their clinical judgment and experience in the face of normal newborn thyroid test results. Hypothyroidism can be acquired after the newborn screening. When clinical symptoms and signs suggest hypothyroidism, regardless of newborn screening results, serum free thyroxine and thyroidstimulating hormone determinations should be performed.",
keywords = "Congenital hypothyroidism, Newborn screening, Thyroid hormone, Thyroid-stimulating hormone",
author = "Rose, {Susan R.} and Brown, {Rosalind S.} and Thomas Foley and Kaplowitz, {Paul B.} and Kaye, {Celia I.} and Sumana Sundararajan and Varma, {Surendra K.} and Brink, {Stuart J.} and Clarke, {William L.} and Janet Silverstein and Rosemary Scales and Laura Laskosz and Schaefer, {G. Bradley} and Bull, {Marilyn J.} and Enns, {Gregory M.} and Gruen, {Jeffrey R.} and Hersh, {Joseph H.} and Mendelsohn, {Nancy J.} and Saal, {Howard M.} and Goldberg, {James D.} and Hanson, {James W.} and Lloyd-Puryear, {Michele A.} and Rasmussen, {Sonja A.} and Paul Spire and Hollowell, {Joseph G.} and Bernet, {Victor J.} and Belin, {Ruth M.} and Burman, {Kenneth D.} and Fein, {Henry G.} and Hennessey, {James V.} and Lamm, {Steven H.} and Mitchell, {Marvin L.} and Park, {Hee Myung} and Robbins, {Richard J.} and Bahn, {Rebecca S.} and Becker, {David V.} and Franklyn, {Jayne A.} and Jacob Robbins and {Van Middlesworth}, Lester and Levitsky, {Lynne L.} and Rogol, {Alan D.} and Sally Radovich",
year = "2006",
month = "6",
doi = "10.1542/peds.2006-0915",
language = "English (US)",
volume = "117",
pages = "2290--2303",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Update of newborn screening and therapy for congenital hypothyroidism

AU - Rose, Susan R.

AU - Brown, Rosalind S.

AU - Foley, Thomas

AU - Kaplowitz, Paul B.

AU - Kaye, Celia I.

AU - Sundararajan, Sumana

AU - Varma, Surendra K.

AU - Brink, Stuart J.

AU - Clarke, William L.

AU - Silverstein, Janet

AU - Scales, Rosemary

AU - Laskosz, Laura

AU - Schaefer, G. Bradley

AU - Bull, Marilyn J.

AU - Enns, Gregory M.

AU - Gruen, Jeffrey R.

AU - Hersh, Joseph H.

AU - Mendelsohn, Nancy J.

AU - Saal, Howard M.

AU - Goldberg, James D.

AU - Hanson, James W.

AU - Lloyd-Puryear, Michele A.

AU - Rasmussen, Sonja A.

AU - Spire, Paul

AU - Hollowell, Joseph G.

AU - Bernet, Victor J.

AU - Belin, Ruth M.

AU - Burman, Kenneth D.

AU - Fein, Henry G.

AU - Hennessey, James V.

AU - Lamm, Steven H.

AU - Mitchell, Marvin L.

AU - Park, Hee Myung

AU - Robbins, Richard J.

AU - Bahn, Rebecca S.

AU - Becker, David V.

AU - Franklyn, Jayne A.

AU - Robbins, Jacob

AU - Van Middlesworth, Lester

AU - Levitsky, Lynne L.

AU - Rogol, Alan D.

AU - Radovich, Sally

PY - 2006/6

Y1 - 2006/6

N2 - Unrecognized congenital hypothyroidism leads to mental retardation. Newborn screening and thyroid therapy started within 2 weeks of age can normalize cognitive development. The primary thyroid-stimulating hormone screening has become standard in many parts of the world. However, newborn thyroid screening is not yet universal in some countries. Initial dosage of 10 to 15 μg/kg levothyroxine is recommended. The goals of thyroid hormone therapy should be to maintain frequent evaluations of total thyroxine or free thyroxine in the upper half of the reference range during the first 3 years of life and to normalize the serum thyroid-stimulating hormone concentration to ensure optimal thyroid hormone dosage and compliance. Improvements in screening and therapy have led to improved developmental outcomes in adults with congenital hypothyroidism who are now in their 20s and 30s. Thyroid hormone regimens used today are more aggressive in targeting early correction of thyroid-stimulating hormone than were those used 20 or even 10 years ago. Thus, newborn infants with congenital hypothyroidism today may have an even better intellectual and neurologic prognosis. Efforts are ongoing to establish the optimal therapy that leads to maximum potential for normal development for infants with congenital hypothyroidism. Remaining controversy centers on infants whose abnormality in neonatal thyroid function is transient or mild and on optimal care of very low birth weight or preterm infants. Of note, thyroid-stimulating hormone is not elevated in central hypothyroidism. An algorithm is proposed for diagnosis and management. Physicians must not relinquish their clinical judgment and experience in the face of normal newborn thyroid test results. Hypothyroidism can be acquired after the newborn screening. When clinical symptoms and signs suggest hypothyroidism, regardless of newborn screening results, serum free thyroxine and thyroidstimulating hormone determinations should be performed.

AB - Unrecognized congenital hypothyroidism leads to mental retardation. Newborn screening and thyroid therapy started within 2 weeks of age can normalize cognitive development. The primary thyroid-stimulating hormone screening has become standard in many parts of the world. However, newborn thyroid screening is not yet universal in some countries. Initial dosage of 10 to 15 μg/kg levothyroxine is recommended. The goals of thyroid hormone therapy should be to maintain frequent evaluations of total thyroxine or free thyroxine in the upper half of the reference range during the first 3 years of life and to normalize the serum thyroid-stimulating hormone concentration to ensure optimal thyroid hormone dosage and compliance. Improvements in screening and therapy have led to improved developmental outcomes in adults with congenital hypothyroidism who are now in their 20s and 30s. Thyroid hormone regimens used today are more aggressive in targeting early correction of thyroid-stimulating hormone than were those used 20 or even 10 years ago. Thus, newborn infants with congenital hypothyroidism today may have an even better intellectual and neurologic prognosis. Efforts are ongoing to establish the optimal therapy that leads to maximum potential for normal development for infants with congenital hypothyroidism. Remaining controversy centers on infants whose abnormality in neonatal thyroid function is transient or mild and on optimal care of very low birth weight or preterm infants. Of note, thyroid-stimulating hormone is not elevated in central hypothyroidism. An algorithm is proposed for diagnosis and management. Physicians must not relinquish their clinical judgment and experience in the face of normal newborn thyroid test results. Hypothyroidism can be acquired after the newborn screening. When clinical symptoms and signs suggest hypothyroidism, regardless of newborn screening results, serum free thyroxine and thyroidstimulating hormone determinations should be performed.

KW - Congenital hypothyroidism

KW - Newborn screening

KW - Thyroid hormone

KW - Thyroid-stimulating hormone

UR - http://www.scopus.com/inward/record.url?scp=33745318070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745318070&partnerID=8YFLogxK

U2 - 10.1542/peds.2006-0915

DO - 10.1542/peds.2006-0915

M3 - Article

C2 - 16740880

AN - SCOPUS:33745318070

VL - 117

SP - 2290

EP - 2303

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -